<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04485052</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI188B201</org_study_id>
    <nct_id>NCT04485052</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of IBI188 in Combination With Azacitidine in Treatment of Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to evaluate safety， tolerability and composite CR of IBI188 plus azacitidine in
      acute myeloid leukemia
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite complete rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Composite CR including complete remission rate and morphologic complete remission with incomplete blood count recovery</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>IBI188+azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive IBI188 every four weeks(Q4W) by intravenous(IV) and azacitidine daily in Day1-7 of each four weeks(Q4W) by subcutaneous(IH)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI188</intervention_name>
    <description>IBI188 will be administered IV, Q4W</description>
    <arm_group_label>IBI188+azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine will be administered daily for 7 days, IH, Q4W</description>
    <arm_group_label>IBI188+azacitidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. AML patients diagnosed according to WHO AML diagnostic criteria in 2016 (except
             M3-type and BCR-ABL positive AML).

          2. Relapsed// refractory AML( ≥18 ys) or newly diagnosed elderly AML unfit for intensive
             chemotherapy( ≥60 ys).

          3. Age ≥18 years old, gender not limited.

          4. ECOG score of 0-2.

          5. Adequate organ function.

        Exclusion Criteria:

          1. Acute promyelocytic leukemia, myeloid sarcoma, acute heterozygous leukemia,
             CMML(accelerated phase and blast phase).

          2. Prior exposure to any anti-CD47 or anti-SIRPα agents.

          3. Major surgery and vaccine treatment within 4 weeks.

          4. Uncontrolled concurrent diseases.

          5. Pregnant or breastfeeding female subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>shijie liu</last_name>
    <phone>18701121959</phone>
    <email>shijie.liu@innoventbio.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 21, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

